Advisors Asset Management Inc. raised its position in shares of Kenvue Inc. (NYSE:KVUE – Free Report) by 8.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 20,371 shares of the company’s stock after buying an additional 1,559 shares during the quarter. Advisors Asset Management Inc.’s holdings in Kenvue were worth $471,000 at the end of the most recent quarter.
A number of other hedge funds also recently bought and sold shares of the company. Riverview Trust Co purchased a new stake in shares of Kenvue in the third quarter worth approximately $30,000. Ashton Thomas Securities LLC purchased a new stake in shares of Kenvue in the third quarter worth approximately $35,000. Deseret Mutual Benefit Administrators lifted its position in shares of Kenvue by 49.7% in the third quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company’s stock worth $45,000 after purchasing an additional 651 shares in the last quarter. Studio Investment Management LLC lifted its position in shares of Kenvue by 52.1% in the second quarter. Studio Investment Management LLC now owns 2,468 shares of the company’s stock worth $45,000 after purchasing an additional 845 shares in the last quarter. Finally, AlphaMark Advisors LLC purchased a new stake in shares of Kenvue in the third quarter worth approximately $77,000. 97.64% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of analysts have recently issued reports on KVUE shares. Piper Sandler increased their price target on shares of Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a research report on Monday, September 23rd. Deutsche Bank Aktiengesellschaft increased their price target on shares of Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. JPMorgan Chase & Co. raised their price objective on shares of Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Jefferies Financial Group assumed coverage on shares of Kenvue in a research report on Tuesday, September 24th. They set a “buy” rating and a $27.00 price objective on the stock. Finally, Bank of America raised their price objective on shares of Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research report on Tuesday, October 22nd. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $22.64.
Kenvue Stock Performance
Shares of KVUE stock opened at $24.12 on Thursday. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The business’s 50 day moving average is $22.89 and its two-hundred day moving average is $20.94. The company has a market cap of $46.24 billion, a PE ratio of 43.85, a price-to-earnings-growth ratio of 2.20 and a beta of 1.36.
Kenvue (NYSE:KVUE – Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.27 by $0.01. The company had revenue of $3.90 billion for the quarter, compared to the consensus estimate of $3.92 billion. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The company’s revenue for the quarter was down .4% compared to the same quarter last year. During the same quarter last year, the company posted $0.31 earnings per share. Equities analysts predict that Kenvue Inc. will post 1.07 EPS for the current year.
Kenvue Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th were paid a $0.205 dividend. The ex-dividend date was Wednesday, November 13th. This represents a $0.82 annualized dividend and a dividend yield of 3.40%. Kenvue’s payout ratio is 149.09%.
Kenvue Profile
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
See Also
- Five stocks we like better than Kenvue
- Health Care Stocks Explained: Why You Might Want to Invest
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- Transportation Stocks Investing
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Ride Out The Recession With These Dividend Kings
- 2 Generic Drug Stocks Ready to Surge in 2025
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.